Cargando…

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial

AIMS/INTRODUCTION: The sodium–glucose cotransporter 2 inhibitor, canagliflozin, reduced kidney failure and cardiovascular events in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial. We carried out a post‐hoc analysis to evaluate the eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wada, Takashi, Mori‐Anai, Kazumi, Kawaguchi, Yutaka, Katsumata, Hideyuki, Tsuda, Hidetaka, Iida, Mitsutaka, Arakawa, Kenji, Jardine, Meg J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756319/ https://www.ncbi.nlm.nih.gov/pubmed/34212533 http://dx.doi.org/10.1111/jdi.13624

Ejemplares similares

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2019)

Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study in Japan
por: Wada, Takashi, et al.
Publicado: (2022)

Canagliflozin Markedly Decreased Proteinuria in a Patient With IgA Nephropathy
por: Aameish, Muhammad, et al.
Publicado: (2021)

Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models
por: Liang, Yin, et al.
Publicado: (2012)

Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy
por: Durkin, Michael, et al.
Publicado: (2020)

Patient profiling in diabetes and role of canagliflozin
por: Amblee, Ambika
Publicado: (2014)

Prolonged diabetic ketoacidosis associated with canagliflozin
por: Sloan, Gordon, et al.
Publicado: (2018)

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
por: Neuen, Brendon L., et al.
Publicado: (2018)

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
por: Zhou, Zien, et al.
Publicado: (2019)

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
por: Woo, Vincent, et al.
Publicado: (2018)

Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease
por: Maruyama, Takashi, et al.
Publicado: (2019)

Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes
por: Takahara, Mitsuyoshi, et al.
Publicado: (2020)

Canagliflozin – Beginning of the journey
por: Pandey, Sunil Kumar, et al.
Publicado: (2014)

Emerging treatments in type 2 diabetes: focus on canagliflozin
por: Rosiak, Marek, et al.
Publicado: (2014)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
por: Triplitt, Curtis, et al.
Publicado: (2015)

Canagliflozin-associated diabetic ketoacidosis: a case report
por: Chai, Peter R., et al.
Publicado: (2017)

Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin
por: Adachi, Junichiro, et al.
Publicado: (2017)

Canagliflozin reverses Th1/Th2 imbalance and promotes podocyte autophagy in rats with membranous nephropathy
por: Lv, Xin, et al.
Publicado: (2022)

Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan
por: Kadowaki, Takashi, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment
por: Inagaki, Nobuya, et al.
Publicado: (2014)

Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program
por: Wang, Katherine M., et al.
Publicado: (2021)

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
por: Weir, Matthew R, et al.
Publicado: (2020)

Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program
por: Yu, Jie, et al.
Publicado: (2021)

Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS)
por: Hassanein, Mohamed, et al.
Publicado: (2017)

Long‐term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2017)

Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes
por: Valentine, Virginia, et al.
Publicado: (2015)

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
por: Bays, Harold E, et al.
Publicado: (2014)

Canagliflozin: a novel treatment option for type 2 diabetes
por: Dietrich, Eric, et al.
Publicado: (2013)

Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature
por: Turner, Jessica, et al.
Publicado: (2016)

Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report
por: Fukuda, Masafumi, et al.
Publicado: (2020)

SUN-700 Fournier’s Gangrene and Diabetic Ketoacidosis Caused by Canagliflozin
por: Stamatiades, George Alexiades, et al.
Publicado: (2020)

A Case of Euglycemic Diabetic Ketoacidosis Following Canagliflozin Therapy
por: Tuna, Kubra M, et al.
Publicado: (2021)

Combination of canagliflozin and puerarin alleviates the lipotoxicity to diabetic kidney in mice
por: Zhu, Qian, et al.
Publicado: (2023)

PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS)
por: Peters, Kirsten E., et al.
Publicado: (2020)

Predictive Factors of Renal Function Decline in Patients with Type 2 Diabetes Treated with Canagliflozin in the Real-Wecan Study
por: Gorgojo-Martinez, Juan J., et al.
Publicado: (2022)

Crystal structure of canagliflozin hemihydrate
por: Liu, Kai-Hang, et al.
Publicado: (2016)

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
por: Charytan, David M, et al.
Publicado: (2023)

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
por: Erondu, Ngozi, et al.
Publicado: (2015)

Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance
por: Inagaki, Nobuya, et al.
Publicado: (2021)

Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus
por: Desai, Mehul, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6n0tj77opu3sasva1q26oriavb